September 29, 2016 12:01 PM ET

Pharmaceuticals

Company Overview of Formula Pharmaceuticals, Inc.

Company Overview

Formula Pharmaceuticals, Inc., a biopharmaceutical company, develops Chimeric Antigen Receptor (“CAR”) immunotherapies to address critical unmet medical needs in cancer. The company primarily focuses on the development of allogeneic CIK-CAR.CD19 for B cell malignancies, followed by the development of allogeneic CIK-CAR.CD33 for myeloid leukemias; a CIK-CAR.PSMA program and other targets for solid tumors; and targets for multiple myeloma. Formula Pharmaceuticals, Inc. was founded in 2009 and is based in Berwyn, Pennsylvania.

1055 Westlakes Drive

Suite 300

Berwyn, PA 19312

United States

Founded in 2009

Phone:

610-727-4172

Fax:

610-896-3546

Key Executives for Formula Pharmaceuticals, Inc.

Founder, Chairman, Chief Executive Officer and President
Co-Founder and Director
Age: 54
Acting Chief Financial Officer
Vice President of Operations
Executive Vice President of Strategic Affairs, General Counsel and Secretary
Age: 52
Compensation as of Fiscal Year 2016.

Formula Pharmaceuticals, Inc. Key Developments

Formula Pharmaceuticals Appoints Malcolm K. Brenner, MD, PhD to its Scientific Advisory Board

Formula Pharmaceuticals, Inc. announced the appointment of Dr. Malcolm K. Brenner, Founding Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, as a member of its Scientific Advisory Board (SAB). The SAB serves as a strategic resource to Formula as it continues to develop Chimeric Antigen Receptor (CAR) immunotherapies leveraging Cytokine Induced Killer (C.I.K.) cells targeting cancer and autoimmune disease. Malcolm Brenner is a professor in the departments of Pediatrics and Medicine, Section of Hematology-Oncology at Baylor College of Medicine. He is also Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, The Methodist Hospital and Texas Children’s Hospital. Dr. Brenner is an associate editor of Blood and of Molecular Therapy, and he is the principal investigator or co-investigator on National Institutes of Health grants.

Formula Pharmaceuticals, Inc. and Rockland Immunochemicals, Inc. Enter into a Collaboration to Develop C.I.K. Car Immunotherapy Pipeline for the Treatment of Cancer

Formula Pharmaceuticals, Inc. and Rockland Immunochemicals, Inc. announced the establishment of a collaboration for the preclinical development of Formula’s Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) cancer immunotherapies at Rockland’s R&D facility. Under the collaboration, Rockland will provide and manage Formula’s specially hired preclinical research team. Further, Rockland will provide the classified research facilities for Formula’s preclinical development needs in its newly established, scalable 60,000 sq ft R&D facility. Formula’s immunotherapy product pipeline is built upon a proprietary, non-viral, allogeneic C.I.K. CAR™ technology platform, which seeks to overcome practical and therapeutic limitations related to existing CAR-T approaches that include viral transfection, autologous blood and T cells. Formula’s C.I.K. CAR™ technology leverages T cell and Natural Killer cell functionality within one effector cell population sourced from healthy donor peripheral or cord blood, which the Company is developing as an off-the-shelf CAR immunotherapy for hematologic and solid tumor indications.

Formula Pharmaceuticals, Inc. Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016

Formula Pharmaceuticals, Inc. Presents at Redefining Early Stage Investments (RESI) Conference 2016, Jan-12-2016 . Venue: Marine's Memorial Club & Hotel, 609 Sutter St, San Francisco, CA 94102, United States.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Formula Pharmaceuticals, Inc., please visit www.formulapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.